Objective Blood vessel epicardial substance (BVES) is a tight junction-associated protein that regulates epithelial-mesenchymal states and is underexpressed in epithelial malignancy. However, the functional impact of BVES loss on tumourigenesis is unknown. Here we define the in vivo role of BVES in colitis-associated cancer (CAC), its cellular function and its relevance to patients with IBD. Design We determined BVES promoter methylation status using an Infinium HumanMethylation450 array screen of patients with UC with and without CAC. We also measured BVES mRNA levels in a tissue microarray consisting of normal colons and CAC samples. Bves −/− and wild-type mice (controls) were administered azoxymethane (AOM) and dextran sodium sulfate (DSS) to induce tumour formation. Last, we used a yeast twohybrid screen to identify BVES interactors and performed mechanistic studies in multiple cell lines to define how BVES reduces c-Myc levels.
INTRODUCTION
Chronic inflammation promotes the development of colorectal cancer (CRC). 1 2 Patients with IBD, for example, have an elevated risk of developing CRC, 3 particularly those who have extensive disease or long disease duration. 4 Although the pathogenesis of inflammatory carcinogenesis remains unclear, at least one component of malignant degeneration is thought to be disruption of intestinal epithelial function as a consequence of chronic inflammation. 5 6 Indeed, pathological changes in adherens and tight junction proteins have been described in colitis and colitis-associated cancer (CAC). [6] [7] [8] In addition to providing junctional integrity between cells, adherens and tight junctional complexes also transduce extracellular signals to direct intracellular programmes ('outside-in' signaling 9 ), such as those controlling
Significance of this study
What is already known on this subject?
▸ Patients with UC are at greater risk of developing colon cancer. ▸ Blood vessel epicardial substance (BVES) is a tight junction protein that regulates epithelial-to-mesenchymal transition in vitro. ▸ c-Myc is an oncogene overexpressed in 50% of all malignancies, including colitis-associated cancer (CAC).
What are the new findings?
▸ BVES promoter hypermethylation is present in CAC and distant uninvolved mucosa. ▸ BVES is underexpressed in patients with CAC compared with normal colonic tissue. ▸ Deletion of Bves promotes colitis-associated tumour multiplicity and dysplasia. ▸ BVES directs the PR61α-protein phosphatase 2A complex to target c-Myc for proteasomal destruction.
How might it impact on clinical practice in the foreseeable future?
▸ BVES promoter hypermethylation status is a potential biomarker to identify patients with UC at risk of cancer. ▸ Our studies demonstrate a new mechanism for regulation of c-Myc, an oncogene that is dysregulated in numerous malignancies. ▸ BVES plays a key role in maintaining the integrity of the colonic mucosa and protecting from inflammatory carcinogenesis, and may represent a therapeutic target in CAC. cellular proliferation and differentiation. For example, E-cadherin can sequester β-catenin at the cell membrane, preventing its nuclear localisation and transcriptional activity. 10 Given that dysregulation of junctional proteins commonly occurs in CAC, understanding their function in normal biology may yield clues to how their dysfunction promotes carcinogenesis. Blood vessel epicardial substance (BVES/POPDC1) is a tight junction-associated protein often silenced in carcinomas secondary to promoter hypermethylation. [11] [12] [13] Restoring BVES expression in CRC cell lines promotes epithelial-like morphology and decreases proliferation, migration, invasion, xenograft tumour growth and metastasis, together indicating broad regulatory capabilities. 11 Conversely, knockdown of BVES in epithelial-like cells induces a mesenchymal-like phenotype characterised by increased proliferation, altered morphology and disorganised cell-cell contacts. 11 Yet how BVES regulates these phenotypes is incompletely understood. Indeed, while several BVES interacting proteins have been identified, 11 their known functions do not explain fully the role of BVES in maintaining epithelial phenotypes. Moreover, how BVES contributes to tumour development has not been tested using genetic approaches.
The transcription factor c-Myc is commonly overexpressed in cancer 14 15 and regulates proliferation, differentiation, apoptosis and epithelial-to-mesenchymal transition. 16 In mouse models of sporadic CRC, decreased c-Myc levels reduce Apc-driven tumourigenesis. 17 In IBD, c-Myc is overexpressed in both inflamed tissues and CAC tumours, 18 and network analysis of CAC samples indicated that c-Myc dysregulation functionally contributes to CAC progression. 19 The c-Myc levels are also increased in experimental models of inflammatory carcinogenesis, such as the azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse model of CAC. 20 Yet the processes responsible for c-Myc dysregulation in inflammatory carcinogenesis remain unidentified. To date, a complex network of proteins-including protein phosphatase 2A (PP2A), Axin1 and GSK3β-has been identified that regulates c-Myc protein levels by modifying the phosphorylation status of c-Myc at two residues, threonine 58 (T58) and serine 62 (S62). 21 Ubiquitylation of c-Myc is initiated by phosphorylation at T58, leading to its ultimate degradation. Given the prominent role of c-Myc in driving oncogenic programmes, understanding mechanisms that control PP2A dephosphorylation of c-Myc may identify new therapeutic targets in inflammatory carcinogenesis.
Here we report that BVES is an important regulator of inflammatory carcinogenesis programmes and promotes c-Myc degradation through an interaction with the PR61α-PP2A complex. We observed that BVES is reduced in human CAC samples, and further that the BVES promoter was hypermethylated within the tumours and at distant unaffected mucosa, suggesting a field effect. Using the AOM/DSS inflammatory carcinogenesis model, we determined that Bves −/− mice demonstrate greater tumour incidence and multiplicity as well as a higher degree of dysplasia and intratumoral proliferation. Furthermore, molecular analysis of Bves −/− tumours revealed increased c-Myc protein and signalling activity. The c-Myc protein was also elevated in intestinal crypts from Bves −/− mice. In line with in vivo results, knockdown of BVES in vitro increased c-Myc stability and consequently increased expression of key c-Myc targets ornithine decarboxylase (ODC) and carbamoyl-phosphate synthetase 2 aspartate transcarbamylase and dihydroorotase (CAD). Conversely, BVES overexpression reduced c-Myc stability and increased c-Myc ubiquitylation. Using a yeast two-hybrid (Y2H) screen, we identified PR61α, the PP2A regulatory subunit critical for c-Myc degradation, as a BVES-interacting protein, and showed that this interaction is required for BVES to modulate cellular c-Myc levels. Thus, we demonstrate that BVES coordinates PR61α-containing PP2A phosphatase complexes to restrict c-Myc protein levels and that BVES is a key suppressor of inflammatory carcinogenesis whose promoter methylation status may define patients with UC at risk of colon cancer.
MATERIALS AND METHODS
Mice, treatments and analysis AOM and DSS were prepared as previously described. 22 Bves −/− mice have been previously described. 23 Detailed protocols can be found in the online supplementary materials and methods section.
BVES promoter methylation analysis
Tissue samples were obtained from colectomy specimens from individuals without UC, individuals with UC but without dysplasia or cancer and patients with UC having high-grade dysplasia (HGD) and/or colon cancer. Clinical information is described in online supplementary tables S1 and S2. Detailed protocols regarding epithelial isolation, methylation array and pyrosequencing can be found in the online supplementary materials and methods section.
See online supplementary materials and methods, for detailed methods regarding cell culture experiments, RNA scope, promoter methylation analyses and mouse analysis.
RESULTS

BVES is downregulated and its promoter is hypermethylated in CAC
As BVES is underexpressed via promoter hypermethylation in CRC, 11 we asked whether the BVES promoter was also hypermethylated in CAC. Therefore, we analysed BVES methylation status in an Infinium HumanMethylation450 array screen of IBD samples. The samples consisted of control patients (control-no UC), patients with UC who did not have cancer (UC-no HGD/CAC) and two different types of samples from patients with UC who had colon cancer: the remote, nonmalignant tissue (UC-concurrent HGD/CAC) and tissue with HGD and/or cancer (HGD/CAC). These analyses demonstrated that the BVES promoter was unmethylated in the controls-no UC (0.1%±0.016%), moderately methylated in UC-no HGD/ CAC (16%±4.7%) and hypermethylated in the HGD/CAC among patients with colitis-associated carcinoma (HGD/CAC, 53%±2.6%) (figure 1A). Furthermore, remote non-neoplastic, mucosal samples (UC-concurrent HGD/CAC) from the same patients who had CAC (HGD/CAC) were hypermethylated (50%±2.6%) to a similar degree as that observed in cancerous tissue. Interestingly, these results suggest that BVES promoter methylation may represent a field effect in CAC and that BVES promoter methylation status may identify patients with UC having concurrent malignancy. To confirm the results derived from the HM450 methylation array studies, we pyrosequenced the BVES promoter in the same samples and again demonstrated low levels of methylation in the UC-no HGD/CAC cases, and higher methylation in both the UC-concurrent HGD/CAC and HGD/CAC cases (figure 1B).
It is possible that BVES promoter methylation, while increased, may not be sufficient to silence its expression. To determine whether BVES promoter methylation indeed reduced its transcription, we tested whether BVES mRNA was downregulated in CAC using high-resolution in situ hybridisation (RNAScope 24 ) in a tissue microarray consisting of normal, UC and CAC samples. BVES mRNA levels were low, but consistently present in normal colonic epithelial cells ( figure 1C ). In UC and CAC samples, however, BVES message was rarely detected and quantification of epithelial staining indicated a fivefold decrease ( p<0.001). Taken together, BVES RNA expression is downregulated in both UC and CAC, most likely due to promoter hypermethylation. Furthermore, as the BVES promoter is hypermethylated in both tumour and non-malignant mucosa in patients with CAC, BVES promoter methylation may serve as a biomarker associated with dysplasia or neoplasia in patients with IBD.
BVES loss promotes CAC development
While BVES underexpression was consistently observed in human CAC, these studies do not establish whether BVES loss actively promotes tumourigenesis. Therefore, we used mouse genetic approaches combined with the AOM/DSS model (figure 2A) to determine if BVES loss contributed to inflammatory tumourigenesis. While Bves was expressed at baseline in the murine colon at both the RNA and protein levels (see online supplementary figure S1), transcriptome profiling of AOM/ DSS-induced tumours in wild-type (WT) mice showed a fivefold decrease in Bves transcripts (figure 2B, left), mirroring the results observed in human CAC. As expected, we also observed changes in other tight junction constituents, supporting previous reports of tight junctional dysregulation in colitis and CAC. 25 We confirmed that Bves message was decreased in AOM/DSS tumour tissue by quantitative PCR (qPCR) in an independent sample set (figure 2B, right). Interestingly, Bves message also decreased in AOM/DSS-treated non-malignant tissue compared with normal colons (figure 2B, right), again suggesting a field effect in inflammatory carcinogenesis. As a result, we hypothesised that complete loss of Bves might promote inflammatory carcinogenesis.
To test the effect of Bves loss in CAC, we compared WT and Bves −/− mice subjected to the same inflammatory carcinogenesis protocol. We first observed that Bves −/− mice lost a greater fraction of body weight compared with WT mice, most notably during cycle 3 (figure 2C), suggesting increased sensitivity to AOM/DSS treatment. Indeed, endoscopy 1 week prior to sacrifice demonstrated increased tumour multiplicity in Bves −/− mice (figure 2D) and this was confirmed at necropsy where we observed 100% tumour penetrance in Bves −/− mice compared with 60% in WT mice (figure 2E). Bves −/− mice also demonstrated increased tumour multiplicity (6.5±0.6 tumours per Bves −/− mouse vs 2.2±0.5 tumours per WT mouse, p<0.001) and tumour size (figure 2E). Furthermore, Bves −/− tumours exhibit more advanced dysplasia compared with WT tumours (figure 2F). Control mice treated with three cycles of DSS-only or a single AOM injection did not develop tumours during this time frame (data not shown). Taken together, these results suggest that BVES underexpression in CAC functionally contributes to inflammatory carcinogenesis.
Increased proliferation and enhanced Wnt activation in
To identify BVES-directed mechanisms responsible for modifying tumourigenesis, we examined proliferation and apoptosis in the tumours of AOM/DSS-treated Bves −/− mice. Proliferation, as measured by phospho-histone H3 staining, was increased in Bves −/− tumours ( figure 3A) . Conversely, staining for cleaved caspase-3 indicated no difference in intratumoral apoptosis between Bves −/− and WT mice (see online supplementary figure   S2 ). As Wnt activation can drive proliferation, we postulated that Wnt signalling might be perturbed in Bves −/− tumours. β-catenin dysregulation is a key indicator of hyperactive Wnt signalling, 26 and β-catenin is also a mutational target in 1,2-dimethylhydrazine/DSS inflammatory carcinogenesis, resulting in increased levels and altered subcellular distribution. 27 Therefore, we analysed β-catenin by immunohistochemistry and observed excessive cytoplasmic and nuclear β-catenin localisation in Bves −/− tumours compared with WT tumours (figure 3B). While these results suggested hyperactive Wnt signalling in Bves −/− tumours, we confirmed this by RNA-seq analysis, which indicated upregulation of established Wnt targets, such as Mmp7, Wisp2 and Rspo4 (figure 3C), in Bves −/− tumours. Ingenuity Pathway Analysis (IPA) 28 of the RNA-seq dataset also indicated hyperactive Wnt networks, such as those regulated by β-catenin and Tcf. Finally, immunoblotting demonstrated greater expression of cyclin D1 and c-jun, two well-characterised Wnt target genes, 29 30 in Bves −/− tumours ( figure 3D ). While previous experiments demonstrated that BVES could regulate Wnt signalling using in vitro, cell-based assays, 11 these findings provide the first in vivo and genetic evidence supporting the hypothesis that BVES regulates Wnt activity.
BVES regulates c-Myc degradation
As c-Myc is a bona fide Wnt transcriptional target, 17 has been identified as a potential biomarker in patients with IBD at risk of CAC 19 and is overexpressed in AOM/DSS tumours, 20 we postulated that c-Myc was dysregulated in Bves figure S5) . We also observed increased mRNA of c-Myc targets Odc and E2f transcription factor 2 (E2f2) (figure 4D) in 'mini-gut' three-dimensional cultures, demonstrating that BVES regulation of c-Myc activity was epithelial cell-autonomous.
As we observed increased c-Myc protein in Bves −/− tumours, we postulated that BVES could regulate c-Myc protein stability. Three cell lines-HEK 293T (non-malignant cell line), Caco2 (CRC cell line that can form a polarised epithelium) and HCE (human corneal epithelial)-which all express BVES (see online supplementary figure S6), 11 were used for BVES knockdown experiments. In all three cell lines, BVES RNA interference increased c-Myc protein levels (figure 5A and see online supplementary figure S7). In addition to increasing total c-Myc protein, we also observed that BVES knockdown reduced T58 phosphorylation, a key post-translational modification which signals for c-Myc degradation by the ubiquitin-proteasome system ( figure 5A ). This increase in c-Myc was functionally relevant as transcript levels of c-Myc targets ODC and CAD were increased with BVES knockdown (figure 5B). observed increased c-Myc polyubiquitylation (figure 5F, left). Moreover, inhibiting the proteasome using MG132 blocked the BVES-induced reduction of c-Myc (figure 5F, right). Hence, our results suggest that BVES promotes the post-translational degradation of c-Myc.
BVES interacts with PR61α, PP2Ac and c-Myc
To identify a molecular mechanism by which BVES orchestrates c-Myc degradation, we conducted a Y2H screen to define the BVES interactome. Characterisation of this interactome using the Protein Analysis Through Evolutionary Relationships Classification System 31 identified a number of biological processes influenced by BVES ( figure 6A) . Interestingly, the screen identified that BVES interacted with four of the five members of the B' family of PP2A regulatory subunits (PPP2R5A, PPP2R5B, PPP2R5D and PPP2R5E). PPP2R5A, also known as PR61α, is a key regulator of PP2A-mediated c-Myc dephosphorylation. PR61α directs the heterotrimeric PP2A complex, consisting of a regulatory, catalytic and structural subunit, to associate with doubly phosphorylated (T58/S62) c-Myc and dephosphorylate S62, resulting in increased levels of monophosphorylated T58 c-Myc species, which signals c-Myc to be degraded by the proteaosome. 32 The BVES-PR61α interaction was then confirmed by directed Y2H (figure 6A) and by exogenous and endogenous co-immunoprecipitation (co-IP) in HEK 293T cells (figure 6B, C). If BVES were interacting with PR61α to promote c-Myc degradation, we hypothesised that BVES would complex with both the PP2A catalytic subunit (PP2Ac) and c-Myc, which we then demonstrated by co-IP (figure 6D, E and see online supplementary figure S9). We further used the proximity ligation assay and confirmed interaction of both exogenous and endogenous BVES with endogenous PR61α and c-Myc ( figure  6F ). Overall, these data indicate that BVES complexes with c-Myc, PR61α and the PP2A catalytic subunit.
BVES is essential for PR61α-mediated c-Myc degradation
PP2A dephosphorylation of S62 requires c-Myc to be phosphorylated at residue T58. 33 If BVES reduces c-Myc through PP2A, we reasoned that c-Myc T58A , a c-Myc mutant resistant to T58 phosphorylation, would escape BVES-induced degradation. Indeed, BVES expression consistently reduced c-Myc WT but had no effect on c-Myc T58A ( figure 7A ). We next hypothesised that knockdown of BVES would ablate PR61α-PP2A-induced c-Myc degradation. Overexpression of PR61α reduced c-Myc protein subtly but consistently, as previously reported 32 ( figure 7B;  compare lanes 1 and 3) . Knocking down BVES, however, rescued PR61α-induced degradation ( figure 7B; compare  lanes 3 and 4) . We then tested whether BVES could enhance PR61α-mediated c-Myc degradation, and indeed, We then sought to determine whether BVES requires PR61α to degrade c-Myc. For these experiments we first mapped the BVES-PR61α interaction domain by serial deletions to the carboxy terminus of BVES. Deleting the carboxy terminal 30 residues, but not the last 15 residues, disrupted the BVES-PR61α interaction as demonstrated by Y2H and by co-IP, thus mapping the interaction domain to residues 330-345 ( figure  7D ). Importantly, this uncoupling mutant (BVES-330) demonstrated reduced affinity for c-Myc ( figure 7E ) and was unable to reduce c-Myc levels (figure 7F), indicating that BVES indeed requires interaction with PR61α to regulate c-Myc. Overall, our results demonstrate that BVES, through PR61α, promotes c-Myc dephosphorylation, destabilisation and destruction, and thus provides mechanistic insight into one manner by which BVES may contribute to inflammatory carcinogenesis.
DISCUSSION
We, and others, have shown that BVES is underexpressed in GI cancers and that restoration of BVES in cancer cell lines induces epithelial features. Here we provide the first genetic evidence that BVES modifies cancer phenotypes, as we demonstrate that mice lacking Bves have increased tumour multiplicity and dysplasia after establishment of inflammatory carcinogenesis. Further, we show Bves −/− tumours have increased c-Myc protein resulting in activation of c-Myc regulated networks. Moreover, we identify that BVES interacts with PR61α, a key regulatory subunit of the PP2A phosphatase complex, and promotes PP2A-mediated c-Myc dephosphorylation leading to c-Myc degradation. Uncoupling the BVES-PR61α interaction blocks BVES-dependent reduction of cellular c-Myc levels. To our knowledge, this is the first junctional-associated protein identified that regulates post-translational c-Myc status. The potential clinical relevance is demonstrated as we observed that BVES is downregulated in CAC likely secondary to promoter methylation. However, perhaps more importantly, we establish that the BVES promoter is also aberrantly methylated in distant, normalappearing tissues in patients with CAC/HGD, suggesting a field effect. Thus, our findings reveal that deletion of BVES promotes CAC and that BVES promoter methylation status may be a clinically important surrogate marker of colitis-associated dysplasia or CAC in patients with IBD.
Chronic colitis has been shown to accelerate genome-wide methylation changes; 34 it has been hypothesised that this greater rate of methylation contributes to the increased cancer risk in patients with colitis by silencing tumour suppressors. Understanding how methylation broadly affects inflammatory tumourigenesis is important to design therapies and screening strategies for patients with IBD. Our report specifically identifies that the BVES promoter is hypermethylated in patients with UC who have CAC. Interestingly, BVES promoter hypermethylation is observed in the cancerous tissue and in the non-malignant mucosa in these patients. Currently, the standard method of cancer screening in patients with IBD, who are at up to a 10-fold elevated risk of developing CAC, 1 is surveillance colonoscopy performed with the hope that cancer will be detected at an early, treatable stage. Yet the detection of neoplasia in the colon can be challenging in individuals with IBD, as the lesions are frequently flat and difficult to detect in a background of acute and chronic inflammatory changes. Our data suggest that aberrant BVES promoter methylation may be a useful biomarker for the presence of CAC, or even dysplasia, and that measuring BVES promoter methylation status could serve as a clinically useful tool to identify patients at risk for colon dysplasia or cancer.
While the molecular pathogenesis of CAC remains incompletely understood, recent work has shown the importance of nuclear factor-κB signalling, 35 the intestinal microbiota, 36 the tumour microenvironment 37 and the innate immune system 38 in regulating inflammatory tumourigenesis. A growing body of evidence also supports the important role of epithelial junctional constituents in inflammation and CRC. For example, mice expressing a dominant negative N-cadherin display disrupted adherens junctions and develop severe inflammation and colitis-associated dysplasia. 39 Likewise, knocking out Junctional Adhesion Molecule-A (JAM-A) results in a dramatic increase in susceptibility to DSS-induced colitis. 8 Here we show that deletion of Bves, a tight junction-associated protein, augments inflammatory carcinogenesis. Indeed, loss of BVES appears to increase tumour initiation and progression. We postulate that this is likely due to dual regulation of Wnt signalling and c-Myc protein degradation. Our results further strengthen the concept that junctional constituents are important regulators of colitis-induced tumour initiation and progression.
In the past decade, BVES has been shown to regulate a variety of cellular processes. For example, a Y2H screen of a mouse heart library identified an interaction between BVES and GEFT, a guanine nucleotide exchange factor. 40 Indeed, it was shown Red staining is positive signal from the PLA interaction, and blue staining is DAPI. In all immunoblots, β-actin was used to ensure loading consistency. All experiments were repeated at least two times.
that expression of BVES modulated cell shape and locomotion, thus linking BVES to Rho-family GTPase signalling. 40 BVES has also been shown, via an interaction with ZO-1, to regulate GEF-H1-mediated RhoA activity. 11 More recently, it was reported that BVES plays a regulatory role in cardiac pacemaking through binding of cyclic AMP and interacting with potassium channel TREK-1. 41 Further, BVES interacts with CAV3, a caveolin expressed in the muscle tissue, and cardiac myocytes in Bves −/− mice have altered calveolar number and size. 42 Thus, BVES, through scaffolding with protein complexes, regulates a wide variety of basic, yet essential, cellular processes.
Our results now expand the known regulatory roles of BVES to include maintaining appropriate c-Myc protein levels. We show that BVES, through its interaction with the PR61α-containing PP2A phosphatase complex, can promote c-Myc degradation and that silencing BVES prevents PR61α-induced degradation of c-Myc. Moreover, mutating BVES so that it is unable to associate with PR61α renders BVES incapable of initiating c-Myc destruction. The post-translational regulation of c-Myc requires coordination of numerous proteins to modify its phosphorylation and ubiquitylation status. 21 Precisely how BVES coordinates the PR61α-PP2A complex remains to be understood, but given that analysis of BVES structure shows no apparent enzymatic motifs in BVES, it is likely that BVES acts as a scaffold allowing for complex formation, similar to AXIN1. 21 Interestingly, in addition to the membranous staining of the BVES-PR61α complex, there also appears to be perinuclear and cytoplasmic localisation (figure 6F), which is consistent with previous reports describing the dynamic subcellular localisation of BVES and its family members. 43 The PP2A family has been associated with tight junctional complexes regulating cellular permeability, but their exact role remains controversial. 44 BVES may bridge PP2A complexes to tight junctions and our report adds a new molecular mechanism for 'outside-in' signalling in the epithelium.
Because c-Myc regulates thousands of genes, even subtle changes in c-Myc expression can have profound effects on cellular transcriptomes that promote tumourigenesis. 45 Indeed, strict regulation of c-Myc is an important component of homeostasis, and this is particularly true in the intestine. Acute expression of c-Myc, for example, dramatically expands the intestinal crypts and results in loss of differentiated cells. 46 Moreover, it has In all immunoblots, β-actin was used as a loading control. All experiments were repeated at least two times. WCL, whole cell lysate.
been shown that c-Myc is essential for Apc-mediated intestinal tumourigenesis. 17 Thus, BVES may serve as an important suppressor of inflammatory tumourigenesis via attenuating excessive c-Myc levels. More broadly, BVES could act as a regulator of c-Myc in a variety of tissues, as BVES is expressed in most epithelial tissues, such as lung, stomach and breast, and its downregulation or promoter hypermethylation has been documented in diverse epithelium. [11] [12] [13] Taking our data together, one can envision a model in which chronic inflammation leads to BVES promoter hypermethylation, resulting in suppression of BVES transcription and reduced cellular protein levels. Loss of BVES impairs PR61α-directed PP2A dephosphorylation of c-Myc, thus favouring increased cellular pools of c-Myc, a potent oncogene, likely, in cooperation with other oncogenic events, contributing to tumour progression (figure 8). Figure 8 Working model of the role of blood vessel epicardial substance (BVES) in regulating c-Myc degradation and colitis-associated cancer development.
